Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 89

1.

Lack of association of proteinuria and clinical outcome in patients treated with bevacizumab for metastatic colorectal cancer.

Iwasa S, Nakajima TE, Nagashima K, Honma Y, Kato K, Hamaguchi T, Yamada Y, Shimada Y.

Anticancer Res. 2013 Jan;33(1):309-16.

PMID:
23267162
[PubMed - indexed for MEDLINE]
2.

Retrospective cohort study on the safety and efficacy of bevacizumab with chemotherapy for metastatic colorectal cancer patients: the HGCSG0801 study.

Sogabe S, Komatsu Y, Yuki S, Kusumi T, Hatanaka K, Nakamura M, Kato T, Miyagishima T, Hosokawa A, Iwanaga I, Sakata Y, Asaka M.

Jpn J Clin Oncol. 2011 Apr;41(4):490-7. doi: 10.1093/jjco/hyr008. Epub 2011 Feb 7.

PMID:
21303790
[PubMed - indexed for MEDLINE]
Free Article
3.

Shorter bevacizumab infusions do not increase the incidence of proteinuria and hypertension.

Shah SR, Gressett Ussery SM, Dowell JE, Marley E, Liticker J, Arriaga Y, Verma U.

Ann Oncol. 2013 Apr;24(4):960-5. doi: 10.1093/annonc/mds593. Epub 2012 Nov 21.

PMID:
23175623
[PubMed - indexed for MEDLINE]
Free Article
4.

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.

Bennouna J, Sastre J, Arnold D, Österlund P, Greil R, Van Cutsem E, von Moos R, Viéitez JM, Bouché O, Borg C, Steffens CC, Alonso-Orduña V, Schlichting C, Reyes-Rivera I, Bendahmane B, André T, Kubicka S; ML18147 Study Investigators.

Lancet Oncol. 2013 Jan;14(1):29-37. doi: 10.1016/S1470-2045(12)70477-1. Epub 2012 Nov 16.

PMID:
23168366
[PubMed - indexed for MEDLINE]
5.

Evaluation of hypertension as a marker of bevacizumab efficacy.

Ryanne Wu R, Lindenberg PA, Slack R, Noone AM, Marshall JL, He AR.

J Gastrointest Cancer. 2009;40(3-4):101-8. doi: 10.1007/s12029-009-9104-9.

PMID:
19921473
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis.

Kang BW, Kim TW, Lee JL, Ryu MH, Chang HM, Yu CS, Kim JC, Kim JH, Kang YK, Lee JS.

Med Oncol. 2009;26(1):32-7. doi: 10.1007/s12032-008-9077-8. Epub 2008 May 22.

PMID:
18498064
[PubMed - indexed for MEDLINE]
7.

The use of high dose d,l-leucovorin in first-line bevacizumab+mFOLFIRI treatment of patients with metastatic colorectal cancer may enhance the antiangiogenic effect of bevacizumab.

Budai B, Nagy T, Láng I, Hitre E.

Angiogenesis. 2013 Jan;16(1):113-21. doi: 10.1007/s10456-012-9303-z. Epub 2012 Sep 6.

PMID:
22956187
[PubMed - indexed for MEDLINE]
8.

Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients.

Scartozzi M, Giampieri R, Maccaroni E, Del Prete M, Faloppi L, Bianconi M, Galizia E, Loretelli C, Belvederesi L, Bittoni A, Cascinu S.

Br J Cancer. 2012 Feb 28;106(5):799-804. doi: 10.1038/bjc.2012.17. Epub 2012 Feb 7.

PMID:
22315053
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab.

Scartozzi M, Galizia E, Chiorrini S, Giampieri R, Berardi R, Pierantoni C, Cascinu S.

Ann Oncol. 2009 Feb;20(2):227-30. doi: 10.1093/annonc/mdn637. Epub 2008 Oct 7.

PMID:
18842611
[PubMed - indexed for MEDLINE]
Free Article
10.

Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.

Masi G, Loupakis F, Salvatore L, Fornaro L, Cremolini C, Cupini S, Ciarlo A, Del Monte F, Cortesi E, Amoroso D, Granetto C, Fontanini G, Sensi E, Lupi C, Andreuccetti M, Falcone A.

Lancet Oncol. 2010 Sep;11(9):845-52. doi: 10.1016/S1470-2045(10)70175-3. Epub 2010 Aug 9.

PMID:
20702138
[PubMed - indexed for MEDLINE]
11.

Bevacizumab-related arterial hypertension as a predictive marker in metastatic colorectal cancer patients.

De Stefano A, Carlomagno C, Pepe S, Bianco R, De Placido S.

Cancer Chemother Pharmacol. 2011 Nov;68(5):1207-13. doi: 10.1007/s00280-011-1604-1. Epub 2011 Mar 16.

PMID:
21409384
[PubMed - indexed for MEDLINE]
12.

A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer.

Cao Y, Tan A, Gao F, Liu L, Liao C, Mo Z.

Int J Colorectal Dis. 2009 Jun;24(6):677-85. doi: 10.1007/s00384-009-0655-9. Epub 2009 Jan 30.

PMID:
19184059
[PubMed - indexed for MEDLINE]
13.

Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).

Schmoll HJ, Cunningham D, Sobrero A, Karapetis CS, Rougier P, Koski SL, Kocakova I, Bondarenko I, Bodoky G, Mainwaring P, Salazar R, Barker P, Mookerjee B, Robertson J, Van Cutsem E.

J Clin Oncol. 2012 Oct 10;30(29):3588-95. doi: 10.1200/JCO.2012.42.5355. Epub 2012 Sep 10.

PMID:
22965961
[PubMed - indexed for MEDLINE]
14.

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.

Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, Erdkamp FL, Vos AH, van Groeningen CJ, Sinnige HA, Richel DJ, Voest EE, Dijkstra JR, Vink-Börger ME, Antonini NF, Mol L, van Krieken JH, Dalesio O, Punt CJ.

N Engl J Med. 2009 Feb 5;360(6):563-72. doi: 10.1056/NEJMoa0808268. Erratum in: N Engl J Med. 2010 Dec 23;363(26):2573.

PMID:
19196673
[PubMed - indexed for MEDLINE]
Free Article
15.

A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200.

Giantonio BJ, Levy DE, O'dwyer PJ, Meropol NJ, Catalano PJ, Benson AB 3rd; Eastern Cooperative Oncology Group.

Ann Oncol. 2006 Sep;17(9):1399-403. Epub 2006 Jul 27.

PMID:
16873427
[PubMed - indexed for MEDLINE]
Free Article
16.

Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.

Tappenden P, Jones R, Paisley S, Carroll C.

Health Technol Assess. 2007 Mar;11(12):1-128, iii-iv. Review.

PMID:
17346499
[PubMed - indexed for MEDLINE]
Free Article
17.

Outcome of first line systemic treatment in elderly compared to younger patients with metastatic colorectal cancer: a retrospective analysis of the CAIRO and CAIRO2 studies of the Dutch Colorectal Cancer Group (DCCG).

Venderbosch S, Doornebal J, Teerenstra S, Lemmens W, Punt CJ, Koopman M.

Acta Oncol. 2012 Sep;51(7):831-9. doi: 10.3109/0284186X.2012.699193. Epub 2012 Jul 16.

PMID:
22794910
[PubMed - indexed for MEDLINE]
18.

Phase I/II study of capecitabine plus oxaliplatin (XELOX) plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer.

Doi T, Boku N, Kato K, Komatsu Y, Yamaguchi K, Muro K, Hamamoto Y, Sato A, Koizumi W, Mizunuma N, Takiuchi H.

Jpn J Clin Oncol. 2010 Oct;40(10):913-20. doi: 10.1093/jjco/hyq069. Epub 2010 May 12.

PMID:
20462981
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study.

Van Cutsem E, Rivera F, Berry S, Kretzschmar A, Michael M, DiBartolomeo M, Mazier MA, Canon JL, Georgoulias V, Peeters M, Bridgewater J, Cunningham D; First BEAT investigators.

Ann Oncol. 2009 Nov;20(11):1842-7. doi: 10.1093/annonc/mdp233. Epub 2009 Apr 30.

PMID:
19406901
[PubMed - indexed for MEDLINE]
Free Article
20.

Bevacizumab plus FOLFIRI-3 in chemotherapy-refractory patients with metastatic colorectal cancer in the era of biotherapies.

Ghiringhelli F, Vincent J, Guiu B, Chauffert B, Ladoire S.

Invest New Drugs. 2012 Apr;30(2):758-64. doi: 10.1007/s10637-010-9575-3. Epub 2010 Nov 6.

PMID:
21057973
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk